FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310335049> ?p ?o ?g. }

• W4310335049 endingPage "204209862211359" @default.
• W4310335049 startingPage "204209862211359" @default.
• W4310335049 abstract "The primary aim of this study was to compare the incidence of venous thromboembolism (VTE) among women initiating ospemifene vs other selective estrogen receptor modulator (SERM) therapies for estrogen-deficiency conditions or breast cancer prevention, and vs women with untreated vulvar and vaginal atrophy (VVA). The secondary objective examined numerous additional safety outcomes.This was a retrospective cohort study using the IBM Watson MarketScan claims database. Women receiving ospemifene, another SERM, or with a new diagnosis of VVA with no treatment from 1 May 2013 to 2 October 2018 were followed through the claims for incident adverse outcomes. The primary outcome was the first occurrence of VTE following cohort entry; secondary outcomes included cerebrovascular events and other adverse events potentially associated with SERM use. Cox models compared the risk of VTE between ospemifene and comparators, using a variety of approaches to control for confounding.The incidence of VTE during the first continuous treatment episode was 3.39 (95% confidence interval [CI]: 1.55-6.43) events per 1,000 person-years (PY) for ospemifene (N = 8977), 11.30 (95% CI: 8.81-14.28) events per 1,000 PY for comparator SERM (N = 12,621), and 10.92 (95% CI: 10.49-11.37) events per 1,000 PY for untreated VVA (N = 242,488). Cox models indicated no increase in risk of VTE for ospemifene vs other SERMs (hazard ratio [HR]: 0.40, 95% CI: 0.19-0.82), and vs untreated VVA (HR: 0.47, 95% CI: 0.24-0.91).This real-world safety analysis found no increase in risk of VTE or other adverse events with use of ospemifene in postmenopausal women.Introduction: This study assessed the risk of venous thromboembolism (VTE) among women treated with ospemifene or another selective estrogen receptor modulator (SERM) therapy and women with untreated vulvar and vaginal atrophy (VVA). Numerous additional safety outcomes were examined.Methods: This study was conducted in the IBM Watson MarketScan claims database. Women receiving ospemifene, another SERM, or with a new diagnosis of VVA with no treatment from 1 May 2013 to 2 October 2018 were followed through the claims for adverse outcomes, including VTE, cerebrovascular events (such as stroke), and other outcomes that might occur with use of a SERM. The analyses compared the risk of VTE between ospemifene and the other two groups, using methods that accounted for differences in patient characteristics between the groups. Because few women over 72 years old used ospemifene, the main analyses examined women aged 54-72 years.Results: The analyses included 8,977 ospemifene users, 12,621 other SERM users, and 242,488 women with untreated VVA. Among women aged 54-72 years, only 9 experienced a VTE during ospemifene treatment, while 55 other SERM users and 1,788 women with untreated VVA had a VTE. The analyses that accounted for differences between the groups confirmed that the risk of VTE was no higher in ospemifene users than in either comparison group.Conclusion: This real-world safety analysis found no increase in risk of VTE or other adverse events with use of ospemifene in postmenopausal women." @default.
• W4310335049 created "2022-12-08" @default.
• W4310335049 creator A5005488440 @default.
• W4310335049 creator A5013470862 @default.
• W4310335049 creator A5014238582 @default.
• W4310335049 creator A5028123620 @default.
• W4310335049 creator A5036967722 @default.
• W4310335049 creator A5082308125 @default.
• W4310335049 creator A5087640246 @default.
• W4310335049 date "2022-01-01" @default.
• W4310335049 modified "2023-09-26" @default.
• W4310335049 title "Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study" @default.
• W4310335049 cites W1503033818 @default.
• W4310335049 cites W1965726545 @default.
• W4310335049 cites W1970642927 @default.
• W4310335049 cites W1971555231 @default.
• W4310335049 cites W1971909806 @default.
• W4310335049 cites W1979376598 @default.
• W4310335049 cites W1982585285 @default.
• W4310335049 cites W1984565138 @default.
• W4310335049 cites W2011779669 @default.
• W4310335049 cites W2013230144 @default.
• W4310335049 cites W2070506018 @default.
• W4310335049 cites W2083266551 @default.
• W4310335049 cites W2097981670 @default.
• W4310335049 cites W2106930529 @default.
• W4310335049 cites W2130041681 @default.
• W4310335049 cites W2130825104 @default.
• W4310335049 cites W2135782176 @default.
• W4310335049 cites W2140881331 @default.
• W4310335049 cites W2294236942 @default.
• W4310335049 cites W2343741170 @default.
• W4310335049 cites W2750849939 @default.
• W4310335049 cites W2883543061 @default.
• W4310335049 cites W2903102772 @default.
• W4310335049 cites W2909997301 @default.
• W4310335049 cites W2911750005 @default.
• W4310335049 cites W3024383879 @default.
• W4310335049 doi "https://doi.org/10.1177/20420986221135931" @default.
• W4310335049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36420373" @default.
• W4310335049 hasPublicationYear "2022" @default.
• W4310335049 type Work @default.
• W4310335049 citedByCount "1" @default.
• W4310335049 countsByYear W43103350492023 @default.
• W4310335049 crossrefType "journal-article" @default.
• W4310335049 hasAuthorship W4310335049A5005488440 @default.
• W4310335049 hasAuthorship W4310335049A5013470862 @default.
• W4310335049 hasAuthorship W4310335049A5014238582 @default.
• W4310335049 hasAuthorship W4310335049A5028123620 @default.
• W4310335049 hasAuthorship W4310335049A5036967722 @default.
• W4310335049 hasAuthorship W4310335049A5082308125 @default.
• W4310335049 hasAuthorship W4310335049A5087640246 @default.
• W4310335049 hasBestOaLocation W43103350491 @default.
• W4310335049 hasConcept C120665830 @default.
• W4310335049 hasConcept C121332964 @default.
• W4310335049 hasConcept C121608353 @default.
• W4310335049 hasConcept C126322002 @default.
• W4310335049 hasConcept C167135981 @default.
• W4310335049 hasConcept C197934379 @default.
• W4310335049 hasConcept C201903717 @default.
• W4310335049 hasConcept C207103383 @default.
• W4310335049 hasConcept C2777176818 @default.
• W4310335049 hasConcept C2777944059 @default.
• W4310335049 hasConcept C29456083 @default.
• W4310335049 hasConcept C44249647 @default.
• W4310335049 hasConcept C50382708 @default.
• W4310335049 hasConcept C530470458 @default.
• W4310335049 hasConcept C61511704 @default.
• W4310335049 hasConcept C71924100 @default.
• W4310335049 hasConcept C72563966 @default.
• W4310335049 hasConceptScore W4310335049C120665830 @default.
• W4310335049 hasConceptScore W4310335049C121332964 @default.
• W4310335049 hasConceptScore W4310335049C121608353 @default.
• W4310335049 hasConceptScore W4310335049C126322002 @default.
• W4310335049 hasConceptScore W4310335049C167135981 @default.
• W4310335049 hasConceptScore W4310335049C197934379 @default.
• W4310335049 hasConceptScore W4310335049C201903717 @default.
• W4310335049 hasConceptScore W4310335049C207103383 @default.
• W4310335049 hasConceptScore W4310335049C2777176818 @default.
• W4310335049 hasConceptScore W4310335049C2777944059 @default.
• W4310335049 hasConceptScore W4310335049C29456083 @default.
• W4310335049 hasConceptScore W4310335049C44249647 @default.
• W4310335049 hasConceptScore W4310335049C50382708 @default.
• W4310335049 hasConceptScore W4310335049C530470458 @default.
• W4310335049 hasConceptScore W4310335049C61511704 @default.
• W4310335049 hasConceptScore W4310335049C71924100 @default.
• W4310335049 hasConceptScore W4310335049C72563966 @default.
• W4310335049 hasFunder F4320323316 @default.
• W4310335049 hasLocation W43103350491 @default.
• W4310335049 hasLocation W43103350492 @default.
• W4310335049 hasLocation W43103350493 @default.
• W4310335049 hasOpenAccess W4310335049 @default.
• W4310335049 hasPrimaryLocation W43103350491 @default.
• W4310335049 hasRelatedWork W2026094606 @default.
• W4310335049 hasRelatedWork W2071258892 @default.
• W4310335049 hasRelatedWork W2071306276 @default.
• W4310335049 hasRelatedWork W2110184485 @default.
• W4310335049 hasRelatedWork W2308159857 @default.

• next